AR and posterior cortical atrophy: Unfortunately, nearly all metastatic PCa cases develop resistance, often through the re-activation of AR signaling by AR gene mutation, amplification, over-expression, alternative splicing, post-translational modification, alteration of co-factor expression, or intratumoral androgen production [5-7].